Giacomo Nuvola, Medical Manager – Oncology at Pivotal, shared a post on LinkedIn:
“EHA 2026: My Top 5 Trials from Stockholm
EHA 2026 showcased impressive innovation across hematologic malignancies. Among the many important datasets presented, these were my top 5 studies:
- MonumenTAL-3 – Talquetamab-based combinations improved outcomes in relapsed/refractory multiple myeloma, further supporting earlier use of GPRC5D-targeted bispecific antibodies.
- PALO/R-ICE – A promising step toward integrating novel immunotherapy approaches into salvage treatment for aggressive B-cell lymphomas.
- MajesTEC-3 – Teclistamab continues to demonstrate the potential of bispecific antibodies beyond heavily pretreated myeloma populations.
- Beat AML – Another reminder that biomarker-driven treatment selection is increasingly becoming standard practice in AML.
- AJX-101 – A novel type II JAK inhibitor showing encouraging activity in myelofibrosis, an area with significant unmet need.
Key themes from EHA 2026:
- Bispecific antibodies continue moving earlier in treatment pathways
- Precision medicine is reshaping AML management
- Innovation in myelofibrosis is accelerating
- The future of hematology is increasingly immune-driven, biomarker-guided, and focused on earlier intervention.”
Other articles featuring Giacomo Nuvola on OncoDaily.